Not All RF Devices are Created Equal

How TriPollar Became the Global Leaders in RF Technology

Established in 2006, TriPollar is manufactured by Pollogen a subsidiary of Lumenis, a pioneer in the medical laser industry for more than 50 years. In fact, they were the first company to use RF technology in an at-home device, taking the benefits and experience from the professional market and making them easily accessible to the home user.

Made in Israel, the global epicentre of aesthetic device technology, Pollogen’s heavy investment in research and development not only ensures that its technology delivers clinically proven results but it also meets the countries strict quality control requirements. 

LED BY INNOVATION

Lumenis has more than 220 registered patents and several FDA clearances, its cutting-edge proprietary technologies ensure that all of the devices under the Lumenis banner are effective, safe, easy-to-use and results-driven.

GLOBAL SUCCESS

TriPollar successfully launched in the UK and US markets more than a decade ago experiencing year-on-year growth. Since then, more than 70 million devices have been sold in these two markets alone.

While one of the world’s largest beauty markets, China launched TriPollar just nine years ago. In excess of 100 million sales later, the TriPollar STOP is now the number one anti-ageing device in the Chinese market, and the third highest selling device in the Home-Use Beauty (HUB) category.

Adding to its international popularity, TriPollar can be found online via The Hut Group, Saks Fifth Avenue, Net-A-Porter, SkinStore and Amazon. Today, TripPollar is sold in more than 60 countries world-wide and now it’s Australia’s turn.

THE RESULTS ARE IN. PROVEN TECHNOLOGY, CONSISTENT RESULTS!

Backed by clinical trials and proven results that consistently deliver, TriPollar continues to grow in popularity and is fast becoming a beauty staple in homes for busy women across the country.

*Clinical Trial Results: and histopathological study of the TriPollar home-use device for body treatments. Sylvie Boisnic, MD, et.al, European Journal of Dermatology 2010

SHOP NOW